ReviewNature reviews. Neurology2011
Determinants of interferon β efficacy in patients with multiple sclerosis.
Review in Nature reviews. Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Interleukin 17F level and interferon β response in patients with multiple sclerosis.JAMA neurology · 2013Trial
- Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.Journal of neuroinflammation · 2012Trial
- Review
- Estrogen receptor alpha signaling in dendritic cells modulates autoimmune disease phenotype in mice.EMBO reports · 2023Article
- Article
- Central Regulatory Role for SIN1 in Interferon γ (IFNγ) Signaling and Generation of Biological Responses.The Journal of biological chemistry · 2017Article
- miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.Journal of molecular neuroscience : MN · 2017Article
- IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.The Journal of biological chemistry · 2016Article
- Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer.Trends in molecular medicine · 2015Review
- Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients.Clinical and experimental immunology · 2015Article
- Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.Expert review of clinical immunology · 2015Review
- Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.Molecular cancer research : MCR · 2014Review
- Drug therapy for multiple sclerosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Review
- Regulatory effects of SKAR in interferon α signaling and its role in the generation of type I IFN responses.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.The Journal of experimental medicine · 2014Article
- MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.PloS one · 2014Article
- Article
- Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.Molecular neurobiology · 2013Article
- Defining and scoring response to IFN-β in multiple sclerosis.Nature reviews. Neurology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with multiple sclerosis (MS) experience clinical relapses or progression of disability, or exhibit evidence of disease activity on MRI, despite the use of disease-modifying therapy. Although evidence clearly supports the efficacy of interferon β (IFN-β) in treating MS, the factors that determine the response to this drug in individual patients have not been fully elucidated. As more treatment options become available, the early identification of factors that can affect or predict the efficacy of agents in individual patients is important, because such knowledge facilitates early switching of treatment. Despite years of research and numerous reports of promising therapy markers for MS, few markers have emerged as clinically useful. Several studies suggest, however, that development of MRI lesions within 6-24 months after the initiation of IFN-β treatment predicts an unfavorable response. In addition, persistently high titers of neutralizing antibodies diminish or abrogate the therapeutic effects of IFN-β, and help to identify patients who do not respond. This Review highlights advances in research on the response to IFN-β in patients with MS and aims to provide a practical approach for incorporating clinical data, biological markers and MRI measures of disease activity into their therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.